ProMIS Neurosciences

ProMIS Neurosciences is dedicated to developing precision antibody therapies for neurodegenerative diseases by selectively targeting toxic misfolded protein oligomers. Its core achievement is the EpiSelect™ computational discovery platform, which has generated a pipeline of candidates, including PMN310 for Alzheimer's disease, now in a Phase 1b trial. The company's strategy is to demonstrate a differentiated safety and efficacy profile by sparing non-toxic protein forms, aiming to advance directly into registrational studies. A recent $175 million financing provides a cash runway through 2027 to execute this plan.

The EpiSelect™ computational discovery platform uses molecular dynamics and conformational energy calculations to predict Disease Specific Epitopes (DSEs) uniquely exposed on toxic misfolded protein oligomers, enabling the design of highly selective antibody therapeutics.

Competes directly with approved anti-amyloid antibodies (lecanemab, donanemab) and other clinical-stage neurotherapeutics. Key differentiation is epitope selectivity designed to avoid plaque binding and associated ARIA. In earlier-stage indications like ALS and Parkinson's, competition is less crowded but growing.